GTHX G1 Therapeutics insider buying and cancer treatment for NASDAQ:GTHX by CryptoFundManager — TradingView


Insider buys: On Nov 18, 2020, Director, Glenn P Muir, purchased 50,000 shares in G1 Therapeutics ( GTHX ) for $675,000.
It has a Market Cap of 544.056M

G1 Therapeutics is a a clinical-stage biopharmaceutical company which engages in the discovery , development, and commercialization of small molecule therapeutics for the treatment of patients with cancer.

Needham’s Chad Messer tells clients that he has high hopes ahead of the February 15 PDUFA date for trilaciclib, its therapy designed to improve outcomes for cancer patients treated with chemotherapy. (

On 10/5/2020 HC Wainwright brokerake Reiterated Rating to Buy and target price to $82.00.

The indicators are bullish on most timeframes, signaling:

Buy in 1h timeframe

Buy on 5h timeframe

Buy on the daily chart

If you are interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.


Source link

Add a comment